Comparative Risk of Atrial Fibrillation Onset in Statin-Treated Patients Initiating Icosapent Ethyl and Omega-3 Acid Ethyl Esters: A Retrospective Cohort Study.

ABSTRACT:

Background

Icosapent ethyl (IPE) and omega-3-acid ethyl esters (docosahexaenoic acid [DHA]/eicosapentaenoic acid [EPA]) are approved as adjunct therapies to statins for reducing cardiovascular events in at-risk patients. However, concerns remain regarding a potential link between IPE and atrial fibrillation (AF). We compared the risk of AF onset in patients who initiated IPE versus DHA/EPA as adjuncts to statin therapy.

Methods

We conducted a retrospective cohort study using the Merative MarketScan Commercial Claims and Medicare Supplemental database in the United States. An active-comparator, new-user study design was applied. Adults diagnosed with dyslipidemia and receiving statin therapy who initiated IPE or DHA/EPA between January 2013 and June 2021 were identified. A pr

SUBMITTER: Sarker J 

PROVIDER: S-EPMC12450000 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature